Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Entero Therapeutics Inc
ENTO
Healthcare
Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of...
celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The Company also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ENTO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 31, 2023 7:00am
New Press Release - First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
Patient screening to initiate; topline data expected by mid-2023 BOCA RATON, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non...
read article.
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 30, 2023 12:32pm
FWBI ....just remember.... Mr. Maggot is a real Dbag ; )
JMHO
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 30, 2023 12:12pm
FWBI ....nice little rally to N.H.O.D $6.63
very low vols...so if I had a position I would have sold it into the strength I might get a position sooner than later ; ) Cheers !
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 30, 2023 11:49am
FWBI.... I'd say this will be double digits sooner than
Later On watch
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 30, 2023 7:00am
New Press Release - First Wave BioPharma to Present at the BIO CEO & Investor Conference
BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced...
read article.
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 25, 2023 3:26pm
FWBI ..... Sheesh...bottom fell out ... LoL
No time to research...... I will stick with what I know No position yet......sold it all at $7 this a.m ....Cheers Wait for the announcement...... somebody wants some paper : ) Cheers 1
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 25, 2023 2:44pm
FWBI ...... Sure is amazing how a Co with a float of
around 830,000 shares outstanding can trade over 17 million in 1 day and only go up $1.02. LoL I'd say there is a distinct possibility that there is a P.O setting up....jmho I will do somemore
...more
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 25, 2023 9:46am
FWBI .... LoL...for got I had a position for the Wifey ; )
Double profit.... Cha Ching !!!!
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 25, 2023 9:32am
FWBI.....sold into the opening strength
Huge swing profit Cha F'king Ching!!!!
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 25, 2023 8:51am
FWBI..... early a.m runner on News release !!!!
Read the previous post.... Cheers !
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 25, 2023 7:00am
New Press Release - First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio
BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced...
read article.
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 24, 2023 3:49pm
FWBI....... Get the picture ?
https://invst.ly/-3bpd 830K shares o/s....currently trading @ $4.50 Cheers !
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 24, 2023 7:00am
New Press Release - First Wave BioPharma to Present at Sequire Biotechnology Conference
BOCA RATON, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced...
read article.
(70)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 18, 2023 6:50am
FWBI....Sheesh eff. today 7 : 1 RS......
That's # 3 since Sept 13/21.....pretty hard to follow this Co due to the lack of transparency. As far as I'm concerned "Caveat Emptor" status for me. https://invst.ly/-1jxq JMHO
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 13, 2023 4:00pm
New Press Release - First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency
BOCA RATON, Fla., Jan. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product